Literature DB >> 17425548

The role of vascular endothelial growth inhibitor in wound healing.

Kevin P Conway1, Patricia Price, Keith G Harding, Wen G Jiang.   

Abstract

Vascular endothelial growth inhibitor (VEGI) is an endothelial cell-specific cytokine and a potent inhibitor of endothelial cell proliferation and angiogenesis. The role of VEGI in angiogenesis related to tissue repair has previously not been investigated. Biopsies from different wound types were analysed by immunohistochemistry and quantitative polymerase chain reaction for the presence of VEGI protein and transcript, respectively. Human vascular endothelial cell line was transfected with VEGI expression plasmid and tested for their in vitro angiogenesis properties. Immunohistochemical staining for VEGI showed reduced expression in the dermal layer of the acute wounds compared with the chronic wound or normal skin. The ability of VEGI to prevent angiogenesis by in vitro assays showed that VEGI acts as a suppressor to the proliferation and microtubule formation of endothelial cells, and the addition of Hepatocyte Growth Factor had little effect on the ability of cell lines expressing the VEGI gene to increase microtubule formation. The aberrant expression of VEGI in different wound types appears to be linked to the outcome of the healing in these wounds. The altered expression of VEGI in chronic wounds constitutes an important target of future therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425548      PMCID: PMC7951696          DOI: 10.1111/j.1742-481X.2006.00295.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  13 in total

1.  Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model.

Authors:  G H Cunnick; W G Jiang; K F Gomez; R E Mansel
Journal:  Biochem Biophys Res Commun       Date:  2001-11-09       Impact factor: 3.575

2.  VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.

Authors:  V Haridas; A Shrivastava; J Su; G L Yu; J Ni; D Liu; S F Chen; Y Ni; S M Ruben; R Gentz; B B Aggarwal
Journal:  Oncogene       Date:  1999-11-11       Impact factor: 9.867

3.  Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients.

Authors:  Christian Parr; Chun H Gan; Gareth Watkins; Wen G Jiang
Journal:  Angiogenesis       Date:  2006-06-07       Impact factor: 9.596

4.  Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily.

Authors:  Y Zhai; J Yu; L Iruela-Arispe; W Q Huang; Z Wang; A J Hayes; J Lu; G Jiang; L Rojas; M E Lippman; J Ni; G L Yu; L Y Li
Journal:  Int J Cancer       Date:  1999-07-02       Impact factor: 7.396

5.  Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.

Authors:  K B Tan; J Harrop; M Reddy; P Young; J Terrett; J Emery; G Moore; A Truneh
Journal:  Gene       Date:  1997-12-19       Impact factor: 3.688

6.  Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter.

Authors:  Qingli Xiao; Chung Y Hsu; Hong Chen; Xiucui Ma; Jan Xu; Jin-Moo Lee
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

7.  Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro.

Authors:  V Trochon; C Mabilat; P Bertrand; Y Legrand; F Smadja-Joffe; C Soria; B Delpech; H Lu
Journal:  Int J Cancer       Date:  1996-05-29       Impact factor: 7.396

8.  VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.

Authors:  Y Zhai; J Ni; G W Jiang; J Lu; L Xing; C Lincoln; K C Carter; F Janat; D Kozak; S Xu; L Rojas; B B Aggarwal; S Ruben; L Y Li; R Gentz; G L Yu
Journal:  FASEB J       Date:  1999-01       Impact factor: 5.191

9.  Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy.

Authors:  Wen G Jiang; Gaynor Davies; Tracey A Martin; Christian Parr; Gareth Watkins; Malcolm D Mason; Kefah Mokbel; Robert E Mansel
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

10.  Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers.

Authors:  Wen G Jiang; Gareth Watkins; Jane Lane; Giles H Cunnick; Anthony Douglas-Jones; Kefah Mokbel; Robert E Mansel
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  11 in total

1.  Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors.

Authors:  Paulina H Liang; Fang Tian; Yi Lu; Biyan Duan; Donna B Stolz; Lu-Yuan Li
Journal:  Angiogenesis       Date:  2010-12-28       Impact factor: 9.596

2.  Activated leukocyte cell adhesion molecule impacts on clinical wound healing and inhibits HaCaT migration.

Authors:  Andrew J Sanders; David G Jiang; Wen G Jiang; Keith G Harding; Girish K Patel
Journal:  Int Wound J       Date:  2011-08-04       Impact factor: 3.315

Review 3.  Vascular precursor cells in tissue injury repair.

Authors:  Xin Shi; Weihong Zhang; Liya Yin; William M Chilian; Jessica Krieger; Ping Zhang
Journal:  Transl Res       Date:  2017-02-21       Impact factor: 7.012

4.  Influence of interleukin-8 (IL-8) and IL-8 receptors on the migration of human keratinocytes, the role of PLC-γ and potential clinical implications.

Authors:  Wen G Jiang; Andrew J Sanders; Fiona Ruge; Keith G Harding
Journal:  Exp Ther Med       Date:  2011-12-01       Impact factor: 2.447

5.  TNFSF15 Modulates Neovascularization and Inflammation.

Authors:  Zhisong Zhang; Lu-Yuan Li
Journal:  Cancer Microenviron       Date:  2012-07-26

6.  TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1.

Authors:  Jian-Wei Qi; Ting-Ting Qin; Li-Xia Xu; Kun Zhang; Gui-Li Yang; Jie Li; Huai-Yuan Xiao; Zhi-Song Zhang; Lu-Yuan Li
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

7.  TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression via activation of JNK-GATA3 signals.

Authors:  Kun Zhang; Hong-Xing Cai; Shan Gao; Gui-Li Yang; Hui-Ting Deng; Guo-Ce Xu; Jihong Han; Qiang-Zhe Zhang; Lu-Yuan Li
Journal:  Oncotarget       Date:  2016-10-25

8.  TNFSF15 Inhibits Blood Retinal Barrier Breakdown Induced by Diabetes.

Authors:  Feng Jiang; Qingzhong Chen; Liming Huang; Ying Wang; Zhuhong Zhang; Xiangda Meng; Yuanyuan Liu; Chunjie Mao; Fang Zheng; Jingkai Zhang; Hua Yan
Journal:  Int J Mol Sci       Date:  2016-04-25       Impact factor: 5.923

9.  Tumour endothelial marker-8 in wound healing and its impact on the proliferation and migration of keratinocytes.

Authors:  Sheila C Wang; Lin Ye; Andrew J Sanders; Fiona Ruge; Keith G Harding; Wen G Jiang
Journal:  Int J Mol Med       Date:  2015-12-11       Impact factor: 4.101

10.  Molecular and cellular impact of Psoriasin (S100A7) on the healing of human wounds.

Authors:  Aravindan Rangaraj; Lin Ye; Andrew James Sanders; Patricia Elaine Price; Keith Gordon Harding; Wen Guo Jiang
Journal:  Exp Ther Med       Date:  2017-03-28       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.